The COVID-19 pandemic has far-reaching impacts on global health product supply chains. The Global Fund works closely with suppliers, implementers and partners to assess the impact on core health product supplies for Global Fund grants. We provide recommendations for implementers on how to manage this impact and offer channels to ensure the continued flow of quality-assured health products through:
As of 14 September 2020, the Global Fund’s product and delivery outlook shows the overall impact of COVID-19 on health product supply chains for Global Fund grants remains at moderate.
The Global Fund’s health product supply response to the pandemic includes regular category-by-category operational risk assessments, recommendations for implementers and other actions. Our document details our latest assessment and recommendations:
Health products are a critical component of a country’s effective emergency response to COVID-19. Countries can access support to secure products through grant flexibilities and the COVID-19 Response Mechanism. Our documents and pages detail procuring:
The Global Fund maintains flexibilities to ensure the continued flow of quality-assured health products and support countries in their response to COVID-19.
Our operational guidance for Principal Recipients relates to requirements for procuring eligible COVID-19 diagnostic products and managing exceptions on quality assurance testing and sampling. Additionally, we regularly update our list of COVID-19 diagnostic products eligible for procurement with Global Fund financing, in line with our Interim Quality Assurance Requirements.
Information related to the quality assurance of health products related to the three diseases is on our Quality Assurance pages.